JPWO2023004425A5 - - Google Patents

Info

Publication number
JPWO2023004425A5
JPWO2023004425A5 JP2024503984A JP2024503984A JPWO2023004425A5 JP WO2023004425 A5 JPWO2023004425 A5 JP WO2023004425A5 JP 2024503984 A JP2024503984 A JP 2024503984A JP 2024503984 A JP2024503984 A JP 2024503984A JP WO2023004425 A5 JPWO2023004425 A5 JP WO2023004425A5
Authority
JP
Japan
Prior art keywords
composition
seq
sequence
chain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527879A (ja
JP2024527879A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074062 external-priority patent/WO2023004425A2/en
Publication of JP2024527879A publication Critical patent/JP2024527879A/ja
Publication of JPWO2023004425A5 publication Critical patent/JPWO2023004425A5/ja
Publication of JP2024527879A5 publication Critical patent/JP2024527879A5/ja
Pending legal-status Critical Current

Links

JP2024503984A 2021-07-23 2022-07-22 養子免疫療法のための機能が強化されたｃｄ３発現ナチュラルキラー細胞 Pending JP2024527879A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163225281P 2021-07-23 2021-07-23
US63/225,281 2021-07-23
US202263310526P 2022-02-15 2022-02-15
US63/310,526 2022-02-15
US202263344931P 2022-05-23 2022-05-23
US63/344,931 2022-05-23
PCT/US2022/074062 WO2023004425A2 (en) 2021-07-23 2022-07-22 Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy

Publications (3)

Publication Number Publication Date
JP2024527879A JP2024527879A (ja) 2024-07-26
JPWO2023004425A5 true JPWO2023004425A5 (https=) 2025-07-29
JP2024527879A5 JP2024527879A5 (https=) 2025-07-29

Family

ID=84978775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503984A Pending JP2024527879A (ja) 2021-07-23 2022-07-22 養子免疫療法のための機能が強化されたｃｄ３発現ナチュラルキラー細胞

Country Status (9)

Country Link
US (1) US20240325443A1 (https=)
EP (1) EP4373501A4 (https=)
JP (1) JP2024527879A (https=)
KR (1) KR20240041964A (https=)
AU (1) AU2022315301A1 (https=)
CA (1) CA3227317A1 (https=)
IL (1) IL310307A (https=)
MX (1) MX2024001073A (https=)
WO (1) WO2023004425A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
AU2024244976A1 (en) * 2023-03-24 2025-09-25 Board Of Regents, The University Of Texas System Engineered natural killer cells with enhanced antitumor memory responses
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
KR20260024372A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
WO2026077446A1 (en) * 2024-10-12 2026-04-16 Nanjing Legend Biotech Co., Ltd. Engineered il-15 constructs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854233C (en) * 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2016054520A2 (en) * 2014-10-03 2016-04-07 The California Institute For Biomedical Research Engineered cell surface proteins and uses thereof
EP3331913A1 (en) * 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
WO2017192536A1 (en) * 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US11752172B2 (en) * 2017-01-04 2023-09-12 Nova Southeastern University Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
WO2019071009A2 (en) * 2017-10-05 2019-04-11 Nantcell, Inc. LIPID ANTIGENS AND L-CELL RECEPTORS ON NK CELLS
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
WO2020205359A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Methods for production of car-nk cells and use thereof
EP3750547A1 (en) * 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
EP4003374A4 (en) * 2019-07-23 2023-08-30 Wen Yang COMPOSITION AND METHODS OF ADOPTIVE IMMUNOTHERAPY

Similar Documents

Publication Publication Date Title
US11679132B2 (en) Methods for enhancing efficacy of therapeutic immune cells
FI3844267T3 (fi) Menetelmät kimeeristä antigeenireseptoria ilmentävien solujen valmistamiseksi
JP2022066290A5 (https=)
JP7604366B2 (ja) 遺伝子操作されたｔ細胞を作製するための方法
US20190194283A1 (en) Immunomodulatory polypeptides and related compositions and methods
IL295604A (en) Methods of making chimeric antigen receptor-expressing cells
EP4516896A2 (en) Methods and compositions for preparing genetically engineered cells
JP2018526033A5 (https=)
JP2017515464A5 (https=)
CN110035768A (zh) 嵌合抗原受体
US10023648B2 (en) Anti-TOSO chimeric antigen receptor and its use
KR20190130024A (ko) 최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료
US20230051885A1 (en) Systems and Methods for Producing Efficacious Regulatory T Cells
AU2025220769A1 (en) Improving immune cell function
JPWO2020117526A5 (https=)
JPWO2023004425A5 (https=)
KR20210111244A (ko) 태반-유래 동종이계 car-t 세포 및 이의 용도
JPWO2022216624A5 (https=)
JPWO2021158523A5 (https=)
JPWO2023278520A5 (https=)
JPWO2023049933A5 (https=)
JPWO2021055349A5 (https=)
JPWO2021142127A5 (https=)
JPWO2022161355A5 (https=)
WO2024254772A1 (zh) 工程化的滋养细胞及其用途